TITILOPE FASIPE to Humans
This is a "connection" page, showing publications TITILOPE FASIPE has written about Humans.
Connection Strength
0.120
-
Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series. Pediatr Blood Cancer. 2024 Aug; 71(8):e31061.
Score: 0.019
-
Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies. J Pediatr Hematol Oncol. 2024 07 01; 46(5):e277-e283.
Score: 0.018
-
Translational Research and Health Equity: Gene Therapies for Sickle Cell Disease as a Case Study. Ethics Hum Res. 2024 May-Jun; 46(3):34-39.
Score: 0.018
-
Still seeking balance in opioid management for acute sickle cell disease pain. Pediatr Blood Cancer. 2022 08; 69(8):e29741.
Score: 0.016
-
Risk factors and co-morbidities in adolescent thromboembolism are different than those in younger children. Thromb Res. 2016 May; 141:178-82.
Score: 0.005
-
Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatr Blood Cancer. 2024 Oct; 71(10):e31219.
Score: 0.005
-
Multi-center retrospective study of children with sickle cell disease admitted to pediatric intensive care units in the United States. Sci Rep. 2023 04 25; 13(1):6758.
Score: 0.004
-
Racial Disparities in Mental Health Disorders in Youth with Chronic Medical Conditions. J Pediatr. 2023 08; 259:113411.
Score: 0.004
-
A Review of Sickle Cell Disease-Reply. JAMA. 2022 11 15; 328(19):1979-1980.
Score: 0.004
-
Sickle Cell Disease: A Review. JAMA. 2022 07 05; 328(1):57-68.
Score: 0.004
-
Severe Pediatric COVID-19 Pneumonia Treated With Adjuvant Anakinra. Hosp Pediatr. 2022 05 01; 12(5):e162-e170.
Score: 0.004
-
Regional anesthesia for sickle cell disease vaso-occlusive crisis: A single-center case series. Pediatr Blood Cancer. 2022 06; 69(6):e29695.
Score: 0.004
-
Spinal cord compression: An unusual sequela of sickle cell disease. Pediatr Blood Cancer. 2022 Nov; 69(11):e29709.
Score: 0.004
-
Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. Am J Hematol. 2020 09; 95(9):E242-E244.
Score: 0.004
-
Perspective: Sistas In Science - Cracking the Glass Ceiling. Ethn Dis. 2018; 28(4):575-578.
Score: 0.003
-
50 Years Ago in The Journal of Pediatrics: Familial Granulocytopenia and Associated Immunoglobulin Abnormality: Report of 3 Cases in Young Brothers. J Pediatr. 2018 03; 194:39.
Score: 0.003